Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences Inc (NASDAQ: PLSE) pioneers bioelectric medicine through its proprietary Nano-Pulse Stimulation technology, offering investors and medical professionals a novel approach to non-thermal therapies. This dedicated news hub provides real-time updates on clinical advancements, regulatory developments, and strategic partnerships shaping the future of targeted cellular treatments.
Access verified information about PLSE's progress in immuno-oncology applications, dermatology research breakthroughs, and system commercialization efforts. Our curated feed includes earnings reports, FDA submissions, peer-reviewed study results, and executive commentary – all essential for evaluating the company's position in the electroceuticals market.
Key updates cover therapeutic trial milestones, intellectual property expansions, and collaborations with leading medical institutions. Bookmark this page to monitor how PLSE's drug-free energy modalities could transform treatment protocols for complex conditions while driving long-term value in the medical device sector.
Pulse Biosciences (PLSE), specializing in Nanosecond Pulsed Field Ablation™ technology, has announced equity inducement awards for five new employees. The Compensation Committee approved stock options to purchase a total of 19,500 shares of company common stock outside the 2017 Equity Incentive Plan, but under the 2017 Inducement Equity Incentive Plan.
The stock options were granted on April 21, 2025, with an exercise price of $17.29 per share, matching the company's closing stock price on that date. These options will vest over a four-year period, with 25% vesting annually, contingent on continued employment with Pulse Biosciences.
Pulse Biosciences (Nasdaq: PLSE), specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 1:30pm PT / 4:30pm ET on the same day. Investors can participate by dialing 1-800-717-1738 or 1-646-307-1865. A live and recorded webcast will be available on the company's investor website.
Pulse Biosciences (NASDAQ: PLSE) announced that its Nanosecond Pulsed Field Ablation (nanosecond PFA) technology will be showcased at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego from April 24-27. The presentation lineup includes a live case transmission featuring the nsPFA 360° catheter with CARTO™ 3 Mapping System from Johnson & Johnson MedTech.
CEO Paul LaViolette highlighted that 2025 will be a milestone year, with plans to initiate an IDE pivotal trial for FDA approval of the Nanosecond PFA 360° Cardiac Catheter System mid-year. The event will feature multiple presentations including:
- A PFA Live Case Summit demonstrating PVI+PWA Using Nanosecond PFA from Na Homolce Hospital, Prague
- A preclinical assessment of dose-based lesion titration
- First-in-Human clinical experience presentation on pulmonary vein isolation
- Initial lab experience with Nanosecond PFA utilizing a novel focal catheter
Pulse Biosciences (PLSE) announced Q4 and full year 2024 financial results, highlighting progress in their Nanosecond Pulsed Field Ablation technology. The company reported positive preliminary results from its first-in-human thyroid nodule study and advanced its pilot program with 8 U.S. centers.
Key financial metrics include:
- Q4 2024 GAAP net loss of $19.4M vs $11.9M in Q4 2023
- Full year 2024 GAAP net loss of $53.6M vs $42.2M in 2023
- Cash position strengthened to $118.0M as of December 31, 2024
- Raised $47.9M through warrant exercises in Q4
The company plans to initiate multiple IDE clinical trials in mid-2025, including studies for benign thyroid nodules and atrial fibrillation treatments. Over 80 patients have been treated with their Cardiac Catheter System in Europe.
Pulse Biosciences (Nasdaq: PLSE), a pioneer in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its participation in the 24th Annual Needham Virtual Health Care Conference. The company's management team is scheduled to deliver a presentation on Thursday, April 10, 2025, at 9:30 am ET.
Investors and interested parties can access both the live and recorded versions of the presentation through the company's investor relations website at investors.pulsebiosciences.com, specifically on the 'Events Calendar and Presentations' page.
Pulse Biosciences (Nasdaq: PLSE), specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 27, 2025, after market close.
The company will host a conference call at 1:30pm PT / 4:30pm ET on the same day. Investors can participate by dialing 1-888-596-4144 with conference ID 5548579. A live and recorded webcast will be available on the company's investor website.
Pulse Biosciences (PLSE), specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced equity inducement grants to 14 new employees. The Compensation Committee approved stock options to purchase up to 165,300 shares of company common stock outside the 2017 Equity Incentive Plan, but under its terms.
The options were granted on February 27 and March 3, 2025, with exercise prices of $18.34 and $17.87 per share respectively, matching the closing prices on those dates. These equity awards feature a four-year time-based vesting schedule, with 25% vesting annually, contingent on continued employment.
Pulse Biosciences (Nasdaq: PLSE), specializing in Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston. The company's management team will deliver a presentation on Wednesday, March 5, 2025, at 10:30 am ET.
Interested parties can access both live and recorded versions of the presentation through the company's investor website, specifically on the 'Events Calendar and Presentations' page at investors.pulsebiosciences.com.
Pulse Biosciences (PLSE) has appointed Jon Skinner as Chief Financial Officer, effective February 3, 2025. Skinner brings extensive healthcare sector experience, most recently serving as VP of FP&A and Investor Relations at Copeland. His prior roles include VP of Finance and Corporate Development at Imperative Care and VP of Finance – Interventional Urology at Teleflex, where he led 25 M&A transactions.
As part of his appointment, Skinner received inducement grants of options to purchase 300,000 shares at $20.93 per share. The options vest over four years, with half based on continuous employment and half tied to achieving product revenue and market capitalization milestones between $2 billion and $5 billion.
The appointment aims to support the company's operational excellence and commercialization of its CellFX nanosecond PFA Platform, which utilizes proprietary Nanosecond Pulsed Field Ablation technology.
Pulse Biosciences (PLSE) announced its nanosecond Pulsed Field Ablation (nsPFA) Percutaneous Electrode System will be featured at the North American Society for Interventional Thyroidology Annual Meeting in Washington D.C., January 31-February 1, 2025. The technology will be highlighted in both clinical science and video sessions.
The company recently obtained FDA 510(k) clearance for its nanosecond percutaneous electrode system for soft tissue ablation. According to CEO Paul LaViolette, the nsPFA technology's nonthermal mechanism limits scarring and fibrosis while sparing critical anatomical structures, making it potentially ideal for treating symptomatic benign thyroid nodules.
The scientific program includes presentations by Dr. Camila Mancera on clinical experience with nsPFA in thyroid nodule patients, and Dr. Stefano Spiezia presenting key nanopulse techniques. Pulse Biosciences will also maintain an exhibit booth at the Mayflower Hotel's East Room.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
